Trevena to Present at the 2022 BIO CEO & Investor Conference
CHESTERBROOK, Pa., Feb. 3, 2022 (GLOBE NEWSWIRE) -- Trevena (Nasdaq: TRVN) will present a corporate overview at the BIO CEO & Investor Conference from February 14-17, 2022. Carrie Bourdow, President & CEO, leads the presentation, which includes a pre-recorded overview and one-on-one virtual meetings. The presentation will be available on-demand starting February 11, 2022. Trevena's pipeline includes innovative treatments for CNS disorders, such as OLINVYK for acute pain and investigational candidates like TRV250 for migraines and TRV734 for opioid use disorder.
- None.
- None.
CHESTERBROOK, Pa., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO, will present a corporate overview at the BIO CEO & Investor Conference being held from February 14th - 17th, 2022.
Additional Conference Details
| Format: | Pre-recorded corporate presentation and one-on-one virtual meetings |
| Presentation Available On-Demand on Friday, February 11, 2022 | |
| Webcast: | Registration Link |
Carrie Bourdow, President & CEO and Barry Shin, Chief Financial Officer, will be scheduling virtual 1x1 meetings and encourage investors to schedule a time during the conference.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes four differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, TRV045 for diabetic neuropathic pain and epilepsy, and TRV027 for acute respiratory distress syndrome and abnormal blood clotting in COVID-19 patients.
For more information, please visit www.Trevena.com
For more information, please contact:
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
(617) 430-7576
PR & Media Contact:
Sasha Bennett
Associate Vice President
Clyde Group
Sasha.Bennett@clydegroup.com
(239) 248-3409
FAQ
What key event is Trevena participating in February 2022?
When will Trevena's presentation be available on-demand?
Who is presenting for Trevena at the BIO CEO & Investor Conference?
What is Trevena's stock symbol?
What does Trevena focus on in their product development?
